# Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle

> **NCT03878745** · NA · COMPLETED · sponsor: **Becton, Dickinson and Company** · enrollment: 55 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DEVICE:** Terumo Nanopass® 34G pen needle
- **DEVICE:** BD Nano™ PRO 32G pen needle

## Key facts

- **NCT ID:** NCT03878745
- **Lead sponsor:** Becton, Dickinson and Company
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-11
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-06-14
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878745, "Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03878745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*